A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.
Epistemonikos ID: 0a0ca1709d70ff3244fa5b83c534371f1806ccac
First added on: Oct 01, 2026